In this manner, we recently developed a small-molecule HIPK2 inhibitor that allosterically interferes with TGF-β–induced Smad3 activity to reduce renal fibrosis in vivo, without affecting the kinase function of HIPK2 and altering its influence on p53 (21). The gene discussed is TP53; the disease is renal fibrosis.